New combination strategies are required for heterogeneity of mantle cell lymphoma (MCL), in order to improve outcomes.
Society of Hematologic Oncology
Latest Content
Clinical evaluation suggests a role for immune checkpoint inhibition in the treatment of patients with lymphomas, but early success has also raised many questions.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
